Latest Clinical Data News

Imugene reported an 86% overall response rate in its BTK inhibitor combination cohort, but ended September with only 0.70 quarters of estimated funding at the reported cash burn. The biotechnology company is assessing further capital sources while navigating a leadership transition and convertible note obligations.

PYC Therapeutics has moved all four RNA drug programs towards their next development milestones, while reporting $655 million in cash and treasury investments at 30 September. The company’s standalone cash balance covers just 1.13 quarters, making its liquid investment portfolio central to the stated funding runway through 2030.

Nexsen is pursuing a second Group B Streptococcus device through a proposed FlashDx joint venture while upgrading StrepSure after interim clinical data shifted its US FDA submission target to early 2027. The diagnostics developer ended September with $3.56 million in cash, equivalent to about four quarters of funding at the latest operating cash-flow rate.

AdAlta is nearing two important development milestones for its EW-001 CAR-T therapy, with a US FDA pre-IND meeting scheduled for 4 November and Australian manufacturing runs expected before year-end. The progress comes with encouraging but early Chinese clinical data, while cash of A$0.65 million leaves limited room for delay.

Arovella Therapeutics has received a $4.03 million FY2026 R&D tax refund, giving the clinical-stage biotech additional cash as it advances its lead therapy ALA-101 towards first-patient dosing. The payment arrives without any accompanying clinical data or disclosed update to the company’s cash runway.

Percheron Therapeutics has secured a funded path towards a Vanderbilt Health-led HMBD-002 trial in high-risk AML and MDS, while ending September with $4.875 million in cash. The biotechnology company also installed a new chief executive and began a preclinical combination study with Invion.

Nyrada has moved its PROTECT-MI heart-attack trial into active recruitment, with four hospitals open and three patients dosed. The biotech also reported supportive US FDA feedback, encouraging preclinical oncology data and AU$13.72 million in cash after a AU$12 million placement.

Cleo Diagnostics has moved its pre-surgical ovarian cancer test into formal Analytical Validation, a key regulatory step before its planned FDA 510(k) submission in the first half of 2027. The three-batch program is expected to take about three months, but no validation results have yet been reported.

Mesoblast has reported a sharp commercial step-up in FY2026, with Ryoncil generating US$115.2 million in net sales and total revenue reaching US$120.3 million. The company has also completed treatment in its 350-patient back-pain trial and refinanced its debt, but remains loss-making and expects to need more capital beyond the next 12 months.

Emyria’s FY26 annual report shows a rapidly expanding psychedelic-assisted care network, with revenue up 210% and treatment capacity reaching 18 beds across four states. The gains came alongside a larger loss, $4.6 million in operating cash outflow and an auditor-highlighted material uncertainty over the company’s ability to continue without further funding.

Vitasora says its remote-care model is now functioning, with estimated September-quarter revenue of US$1.028 million and a September exit rate of about US$17,400 a day. The next test is execution: turning planned Care Coordinator hiring into sustained, reconciled revenue and operational break-even.

Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.